Bergen, Norway, 14 December 2017 - Reference is made to the stock exchange
notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 17 November
2017 where the Company announced that the board of directors of the Company had
resolved to increase the Company's share capital in connection with the exercise
options pursuant to the Company's employee share option program. A total of
165,000 options were exercised at an average subscription price of NOK 9.73 per
share. The share capital increase has been duly registered in the Norwegian
Register of Business Enterprises. Following such registration, the Company's
share capital is NOK 4,992,220 divided into 49,922,200 shares, each with a
nominal value of NOK 0.10.
-End-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
Tom Henrik Sundby
Finance Director, BerGenBio ASA
tom.sundby@bergenbio.com
+47 477 54 415
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.